Neovascular age-related macular degeneration
Not recruitingStudy on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration
Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration
- Disease:Neovascular age-related macular degeneration
- Substances:AfliberceptRanibizumab
Hungary- Participants:18–64 years · 65+ years
- Substances:Aflibercept
- Sponsor:AbbVie Deutschland GmbH & Co. KG














